Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
The National Institutes of Health (nih), U.s. Dept. of Health and Human Services (dhhs), U.s. Government currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct art units, indicating a focused but multi-disciplinary approach to its medical and biological innovations. The distinct examiners assigned to these cases suggest that each pending action is handled by a different individual, preventing a single point of bottleneck for the organization's current filings.
MINA HAGHIGHATIAN is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This workload for the busiest examiner reflects a decentralized prosecution landscape where no individual official carries a disproportionate share of the total pending workload. Practitioners should note that the concentration in 2 distinct art units may lead to consistent examination standards despite the variety of examiners involved. The presence of 4 distinct examiners across these specialized technical groups suggests a broad range of individual perspectives.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.1% | +39.3% |
| ANSARI, TAHMINA N | 1 | 85.4% | +18.6% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| GANGLE, BRIAN J | 1 | 76.7% | +14.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852335 | METHODS AND COMPOSITIONS FOR POTENTIATION OF A LIGAND | HAGHIGHATIAN, MINA | — |
| 18825923 | SYSTEMS AND METHODS FOR LEARNING ANATOMICALLY CONSISTENT EMBEDDING FOR CHEST RADIOGRAPHY | ANSARI, TAHMINA N | — |
| 18552417 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING SARS-COV-2 ANTIGENS AND METHODS OF USE | AEDER, SEAN E | — |
| 18217857 | BACTERIAL BIOFILMS AND CANCER | GANGLE, BRIAN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18852335 | METHODS AND COMPOSITIONS FOR POTENTIATION OF A LIGAND | HAGHIGHATIAN, MINA | — |
| 18825923 | SYSTEMS AND METHODS FOR LEARNING ANATOMICALLY CONSISTENT EMBEDDING FOR CHEST RADIOGRAPHY | ANSARI, TAHMINA N | — |
| 18552417 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING SARS-COV-2 ANTIGENS AND METHODS OF USE | AEDER, SEAN E | — |
| 18217857 | BACTERIAL BIOFILMS AND CANCER | GANGLE, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18852335 | METHODS AND COMPOSITIONS FOR POTENTIATION OF A LIGAND | HAGHIGHATIAN, MINA | — | §102§103§112Other | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18825923 | SYSTEMS AND METHODS FOR LEARNING ANATOMICALLY CONSISTENT EMBEDDING FOR CHEST RADIOGRAPHY | ANSARI, TAHMINA N | — | §102§103 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18552417 | PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING SARS-COV-2 ANTIGENS AND METHODS OF USE | AEDER, SEAN E | 1642 | §102§112 | Final Rejection | — | Pending | Sep 25, 2023 |
| 18217857 | BACTERIAL BIOFILMS AND CANCER | GANGLE, BRIAN J | 1645 | §102§103§112Other | Non-Final OA | — | Pending | Jul 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial